News
Sixty seconds on . . . solanezumab
BMJ 2016; 355 doi: https://doi.org/10.1136/bmj.i6389 (Published 29 November 2016) Cite this as: BMJ 2016;355:i6389
- Nigel Hawkes
- London
More bad news on drugs for Alzheimer’s disease?
Yes, another drug has failed in phase III trials. This one is solanezumab, whose demise was a three act drama that’s finally seen the curtain fall.1 2 3
Was that a surprise?
Not really. Alzheimer’s disease is the graveyard of drug discovery. One study found that of 244 compounds tested between 2000 and 2014 only one was ever licensed, a failure rate of 99.6%.4
That implies everybody’s doing something wrong
Or …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.